Black Diamond Therapeutics Inc expected to post a loss of 29 cents a share - Earnings Preview

Black Diamond Therapeutics

07/03/2025 12:32

Black Diamond Therapeutics Inc BDTX.OQ BDTX.O is expected to show no change in quarterly revenue when it reports  results on May 7 (estimated) for the period ending March 31 2025

​LSEG's mean analyst estimate for Black Diamond Therapeutics Inc is for a loss of 29 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Black Diamond Therapeutics Inc is $15.00​, above​ its last closing price of $1.90. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Dec. 31 2024
-0.31
-0.28
Beat
11
Sep. 30 2024
-0.38
-0.37
-0.28
Beat
25.1
Jun. 30 2024
-0.38
-0.39
-0.36
Beat
7​
Mar. 31 2024
-0.42
-0.43
-0.35
Beat
19.5
​​Dec. 31 2023
-0.45
-0.47
-0.34
Beat
27
Sep. 30 2023
-0.44
-0.49
-0.45
Beat
7.5​
Jun. 30 2023
-0.54
-0.54
-0.52
Beat
3
Mar. 31 2023
-0.61
-0.61
-0.57
Beat
6.2

This summary was machine generated March 7 at 12:32 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)